期刊簡介 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | ACTA ONCOLOGICA LetPub Score 6.5
50 ratings
Rate
Reputation 7.5 Influence 5.2 Speed 8.8 | ||||||||||||||||||||||||
期刊簡稱 | ACTA ONCOL | ||||||||||||||||||||||||
ISSN | 0284-186X | ||||||||||||||||||||||||
E-ISSN | 1651-226X | ||||||||||||||||||||||||
h-index | 88 | ||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||
自引率 (2023-2024) | 7.40%自引率趨勢 | ||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||
官方網站 | http://www.tandfonline.com/toc/ionc20/current#.V3t2DtJ9600 | ||||||||||||||||||||||||
在線稿件提交 | https://mc.manuscriptcentral.com/sonc | ||||||||||||||||||||||||
開放訪問 | No | ||||||||||||||||||||||||
出版商 | Informa Healthcare | ||||||||||||||||||||||||
主題領域 | 医学 | ||||||||||||||||||||||||
出版國/地區 | NORWAY | ||||||||||||||||||||||||
發行頻率 | 隔月刊行 | ||||||||||||||||||||||||
創刊年 | 1987 | ||||||||||||||||||||||||
每年文章數 | 210每年文章數趨勢 | ||||||||||||||||||||||||
黃金OA百分比 | 34.24% | ||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q3
| ||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0284-186X%5BISSN%5D | ||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Average 3 Month(s) | ||||||||||||||||||||||||
競爭力 * | 來自作者的數據: About 50% | ||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[ACTA ONCOLOGICA] 的評論 | 撰寫評論 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 13:16:23 評論於 All questions must be answered systematically without omission; try to fulfill any additional experiments suggested in the comments, provide reasonable explanations if some cannot be conducted; make sure to cite the literature recommended by the reviewer and discuss it thoroughly; double-check the modifications made to the initial draft before submitting the revised manuscript(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 09:08:02 評論於 After the reviewer completes the scoring of the chapter, they need to write a comprehensive review opinion. This usually includes a brief summary of the article content, evaluation of the article's innovation points, pointing out the shortcomings of the article, and providing suggestions for how the editor should handle the article(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 修然小公主 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 23:48:26 評論於 How to respond to reviewer comments?(0) 讚! | 修然小公主 |
作者: Oswald Edie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 23:29:16 評論於 What are the opinions and suggestions of the journal editors? What are the opinions and suggestions of the reviewer? What are the differences between the two?(0) 讚! | Oswald Edie |
作者: Squires 領域: 医学 審稿時間: 3.0 month(s) 結果: 修改後接受 撰寫評論 |
2018-09-28 14:50:30 評論於 I feel that this journal has not been very good in the past two years, and the quality has gone down. (0) 讚! | Squires |
作者: Jocelyn Albert 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-09-28 10:57:33 評論於 Review speed: 3.0 Experience sharing: I feel that this journal is not as good as before in the past two years, and the reviewers are not as serious as before(0) 讚! | Jocelyn Albert |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 08:57:51 評論於 3-point edge, hoping to maintain stability, a slight increase is also good(0) 讚! | 凌霄高洁 |
作者: Gale Onions 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2015-08-23 20:25:04 評論於 Submission success rate: 5.0 Experience sharing: The official magazine of the four Nordic countries, with the majority of authors from these four countries, followed by Europe, a few from the United States, rare from Asia, and none from China in the past two years. The difficulty of submission is very high, with a success rate of about 15% or less. Usually, editors will eliminate a batch of submissions similar to domestic core journals!(0) 讚! | Gale Onions |
作者: 哈罗德耶克斯 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2013-04-12 10:27:07 評論於 Review speed: 3.0 | Submission acceptance rate: 50.0 Experience sharing: In April 2012, I submitted an article to this journal. The first review reply came in one month, saying they were interested and requested revisions (no rejection, I thought the reviewers were kind). So I made the revisions and resubmitted. After two months with no response, I sent a reminder email, and got a quick reply. The reviewers thought the experiments were too simple and requested additional experiments (they were really kind). It took nearly 2 months to complete the additional experiments and resubmit. After one month with no news, I sent another reminder, expressing concern about the lengthy review process and urging for a faster pace. The reply promised faster processing. Less than 2 weeks later, they replied asking for language polishing. After polishing, I resubmitted and received acceptance 3 days later. The whole process took nearly 8 months(0) 讚! | 哈罗德耶克斯 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-06-29 20:34:09 評論於 It looks bullish. If it goes up again tomorrow, it is expected to break through 3 points(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-04-16 20:36:58 評論於 EF has just been found in 2009(0) 讚! | 凌霄高洁 |
作者: 九阴琴心 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-04-16 19:49:49 評論於 EF has just been found in 2009(0) 讚! | 九阴琴心 |
作者: Eli Josh 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2010-11-08 10:51:58 評論於 My article was rejected after being reviewed for 3 months. It's very straightforward. A bit frustrated, if they were going to reject it, they should have done it sooner instead of dragging it out for so long(0) 讚! | Eli Josh |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2009-12-15 20:13:27 評論於 Field: Oncology Country: Sweden Submission Time: May 2006 Review Time: Initial review 8 weeks, major revision once, return after two months, minor revision, then return after two weeks for acceptance. Publication Fee: Free Journal Periodicity: 8 issues per year Personal Comment: This journal is worth considering for colleagues studying tumors. It leans toward the basic side, and its Impact Factor has risen rapidly in recent years, from a few points to a certain difficulty level. Full-text access is available for free online six months after publication(0) 讚! | 凌霄高洁 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us